This study evaluates safety, long-term clinical outcomes and associated treatment factors following intravitreal triple injection of recombinant tissue plasminogen activator (rtPA), SF6 gas, and Bevacizumab due to acute SMH secondary to AMD. Here, PLAT is linked to age-related macular degeneration.